Literature DB >> 11313807

Expansion of tropism of a feline parvovirus to target a human tumor cell line by display of an alpha(v) integrin binding peptide on the capsid.

I H Maxwell1, J T Chapman, L C Scherrer, A L Spitzer, S Leptihn, F Maxwell, J A Corsini.   

Abstract

The autonomous parvoviruses are small, non-enveloped, single strand DNA viruses. They occur in many species and they have oncolytic properties. We are modifying the capsid of feline panleukopenia virus (FPV), a parvovirus which normally infects feline cells, with the goal of targeting human tumor cells for potential cancer therapy. Using recombinant viruses transducing a luciferase reporter, we show that insertion of a cyclically constrained, integrin-binding peptide at an exposed position on the FPV capsid enables transduction of an alpha(v) integrin-expressing human rhabdomyosarcoma cell line (Rh18A). These cells were not transduced by virus with the unmodified FPV capsid. Transduction of Rh18A was specifically inhibited by an alpha(v) integrin blocking antibody. However, other human tumor lines expressing alpha(v) integrins were not transduced by virus with either the modified or unmodified capsid. We conclude that modification of the FPV capsid to bind alpha(v) integrins can contribute to, but is not generally sufficient for, redirecting infection to human tumor cells. The permissiveness of Rh18A cells presumably involves additional factors unique to this line among various human cell lines tested.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313807     DOI: 10.1038/sj.gt.3301399

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

1.  Development of a reverse genetics system for a feline panleukopenia virus.

Authors:  Nan Cheng; Yongkun Zhao; Qiuxue Han; Weijiao Zhang; Ji Xi; Yongle Yu; Hualei Wang; Guohua Li; Yuwei Gao; Songtao Yang; Weiquan Liu; Xianzhu Xia
Journal:  Virus Genes       Date:  2018-12-05       Impact factor: 2.332

2.  Developing novel oncolytic adenoviruses through bioselection.

Authors:  Wen Yan; Galila Kitzes; Farid Dormishian; Lynda Hawkins; Adam Sampson-Johannes; Josh Watanabe; Jenny Holt; Vivian Lee; Thomas Dubensky; Ali Fattaey; Terry Hermiston; Allan Balmain; Yuqiao Shen
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 3.  Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.

Authors:  Julia Fakhiri; Dirk Grimm
Journal:  Mol Ther       Date:  2021-04-05       Impact factor: 11.454

4.  Theranostic potential of oncolytic vaccinia virus.

Authors:  Juan J Rojas; Steve H Thorne
Journal:  Theranostics       Date:  2012-04-05       Impact factor: 11.556

5.  The Promise of Integrins as Effective Targets for Anticancer Agents.

Authors:  William L. Rust; Stephen W. Carper; George E. Plopper
Journal:  J Biomed Biotechnol       Date:  2002

Review 6.  Non-human viruses developed as therapeutic agent for use in humans.

Authors:  Danijela Koppers-Lalic; Rob C Hoeben
Journal:  Rev Med Virol       Date:  2011-05-11       Impact factor: 6.989

Review 7.  Oncolytic viruses in cancer therapy.

Authors:  Markus J V Vähä-Koskela; Jari E Heikkilä; Ari E Hinkkanen
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.